Clinical and biological characteristics of the KSHV+ subgroup
| . | KSHV-MCD flare (n = 16) . | Postrituximab KSHV-MCD flare (n = 2)∗ . | KSHV+ controls (n = 19) . | P . |
|---|---|---|---|---|
| Sex, male, n (%) | 15 (94) | 1 (50) | 16 (84) | .20 |
| Age, median (IQR), y | 56 (50-67) | 60 (40-79) | 60 (43-72) | .91 |
| KSHV-related diseases, n (%) | ||||
| MCD | 16 (100) | 2 (100) | 10 (52) | <.01 |
| KS | 7 (44) | 0 | 8 (42) | .75 |
| PEL | 0 | 0 | 3 (16) | .35 |
| DLBCL | 0 | 0 | 1 (5) | >.99 |
| Asymptomatic KSHV infection | — | — | 2 (11) | — |
| Type of immunosuppression, n (%) | ||||
| HIV+ | 8 (50) | 1 (50) | 9 (47) | >.99 |
| Positive HIV viral load | 5 (31) | 1 (50) | 2 (11) | .18 |
| Organ transplant recipient | 0 | 0 | 1 (5) | >.99 |
| Biological findings, median (IQR) | ||||
| CRP | 72 (36-115) | 216 (142-290) | 2 (0-34) | <.001 |
| KSHV viral load, log copies per mL | 6.4 (5.9-6.7) | 5.6 (5-6.3) | 3.9 (0.7-4.7) | <.001 |
| History of KSHV-related disease treatment | ||||
| Etoposide, n (%) | 9 (56) | 1 (50) | 6 (32) | .37 |
| Rituximab, n (%) | 7 (44) | 2 (100) | 5 (26) | .17 |
| Duration since last rituximab infusion, median [IQR], mo | 23 (20-42) | 0.4 (0.3-0.5) | 13 (8-60) | .33† |
| Pegylated liposomal doxorubicin, n (%) | 1 (6) | 0 | 4 (21) | .51 |
| Pembrolizumab, n (%) | 2 (13) | 0 | 2 (11) | >.99 |
| Other treatments, n (%) | 1 (6) | 0 | 7 (37) | .08 |
| . | KSHV-MCD flare (n = 16) . | Postrituximab KSHV-MCD flare (n = 2)∗ . | KSHV+ controls (n = 19) . | P . |
|---|---|---|---|---|
| Sex, male, n (%) | 15 (94) | 1 (50) | 16 (84) | .20 |
| Age, median (IQR), y | 56 (50-67) | 60 (40-79) | 60 (43-72) | .91 |
| KSHV-related diseases, n (%) | ||||
| MCD | 16 (100) | 2 (100) | 10 (52) | <.01 |
| KS | 7 (44) | 0 | 8 (42) | .75 |
| PEL | 0 | 0 | 3 (16) | .35 |
| DLBCL | 0 | 0 | 1 (5) | >.99 |
| Asymptomatic KSHV infection | — | — | 2 (11) | — |
| Type of immunosuppression, n (%) | ||||
| HIV+ | 8 (50) | 1 (50) | 9 (47) | >.99 |
| Positive HIV viral load | 5 (31) | 1 (50) | 2 (11) | .18 |
| Organ transplant recipient | 0 | 0 | 1 (5) | >.99 |
| Biological findings, median (IQR) | ||||
| CRP | 72 (36-115) | 216 (142-290) | 2 (0-34) | <.001 |
| KSHV viral load, log copies per mL | 6.4 (5.9-6.7) | 5.6 (5-6.3) | 3.9 (0.7-4.7) | <.001 |
| History of KSHV-related disease treatment | ||||
| Etoposide, n (%) | 9 (56) | 1 (50) | 6 (32) | .37 |
| Rituximab, n (%) | 7 (44) | 2 (100) | 5 (26) | .17 |
| Duration since last rituximab infusion, median [IQR], mo | 23 (20-42) | 0.4 (0.3-0.5) | 13 (8-60) | .33† |
| Pegylated liposomal doxorubicin, n (%) | 1 (6) | 0 | 4 (21) | .51 |
| Pembrolizumab, n (%) | 2 (13) | 0 | 2 (11) | >.99 |
| Other treatments, n (%) | 1 (6) | 0 | 7 (37) | .08 |